We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Genetic Variants Identified for Bloom Syndrome

By LabMedica International staff writers
Posted on 24 Jun 2015
Image: The face of a patient with Bloom syndrome or congenital telangiectatic erythema, a rare autosomal recessive disorder (Photo courtesy of Dr. Amira M. Elbendary).
Image: The face of a patient with Bloom syndrome or congenital telangiectatic erythema, a rare autosomal recessive disorder (Photo courtesy of Dr. Amira M. Elbendary).
For many diseases, testing is limited to detecting only the most common variants that are associated with a particular ethnicity, such as Ashkenazi Jews, who are known to have genes that make them susceptible to a variety of diseases.

Among those disease affecting Ashkenazi Jews is the rare condition Bloom syndrome, which causes varying degrees of immunodeficiency as well as sun sensitivity, telangiectatic erythema of the face, and stunted growth.

Scientists at the molecular information company Good Start Genetics, Inc. (Cambridge, MA, USA) conducted an extensive literature review and examining sequence-based, laboratory and bioinformatics evidence. Study participants were 22,864 ethnically diverse individuals referred by fertility clinics from across the USA for routine carrier screening between April 2012 and February 2014. Informed consent processes were followed for each patient.

The investigators identified 50 genetic variants of the gene for Bloom syndrome (BLM) that it deemed pathogenic, or associated with Bloom syndrome. The literature review turned up 76 variants, but some were excluded from the test's list of pathogenic sequences following further scrutiny by the scientists. During screening, they detected 39 carriers of 11 different mutations that it had previously identified as pathogenic. Using a subset of the data, the company found the carrier rate to be 1/510 subjects, consistent with the expected ratio based on prior knowledge.

The team identified 16 novel "truncating" variants that can be identified as pathogenic by their genetic sequence alone, and do not require laboratory experiments or statistical evidence to prove their association with the disease. More than a quarter of the carriers (28%) had one of the previously unidentified truncating genetic variants. About 40% of all carriers of Bloom syndrome genes had a known pathogenic variant that, to their knowledge, that was not included in any other commercial carrier screening test.

The authors concluded that their data indicate that using a comprehensive panel of rigorously evaluated variants for carrier screening a pan-ethnic population provides major advantages in terms of increased rates of carrier detection. Limited genotyping panels would have missed the carrier status of many of the individuals they identified because they were not carriers of the major ethnically specific common variants. The study was published online on April 23, 2015, in the journal Molecular Genetics & Genomic Medicine.

Related Links:

Good Start Genetics Inc.


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay

Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more

Microbiology

view channel
Image: The SMART-ID Assay delivers broad pathogen detection without the need for culture (Photo courtesy of Scanogen)

Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples

Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
GLOBE SCIENTIFIC, LLC